Sign in Subscribe
Cardiac patients

GLP-1RA Reduces Heart Failure Exacerbations and Improves Patient Functionality, But Does Not Impact Overall Mortality

Strategic Insights

— 1 min read

Current study results on Heart Disorders and Diseases - Heart Failure have revealed that GLP-1RA (glucagon-like peptide-1 receptor agonists) can play a significant role in reducing heart failure exacerbations, improving patient's functional status, and impacting the global healthcare burden of heart failure. The research, conducted by the University of Illinois, showed that GLP-1RA reduced the composite event of cardiovascular mortality and worsening heart failure exacerbation by 36% compared to placebo. However, the study did not find any significant difference in cardiovascular deaths between the two groups.

Key Takeaways:

  • The study included 4474 patients with heart failure and preserved or mildly reduced ejection fraction, with 2278 (50.91%) receiving GLP-1RA and 2196 (49.01%) receiving a placebo.
  • GLP-1RA reduced heart failure exacerbations by 48.4% compared to placebo, with a significant difference observed in subgroup analysis.
  • The Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) was favorable for GLP-1RA, with a Stand Mean Difference (SMD) of 7.38 (95% CI: 5.51-9.26).
  • GLP-1RA improved patient functionality, with an increase in 6-minute walk distance and a decrease in body weight.
  • The study did not find any overall mortality benefit with GLP-1RA compared to placebo.

Statistics:

  • 4474 patients with heart failure (preserved and mildly reduced ejection fraction) were included in the study.
  • 2278 (50.91%) patients received GLP-1RA, while 2196 (49.01%) patients received a placebo.
  • Cardiovascular mortality and worsening heart failure exacerbation were reduced by 36% with GLP-1RA compared to placebo.
  • Heart failure exacerbations were reduced by 48.4% with GLP-1RA compared to placebo.
  • Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) was favorable for GLP-1RA, with a Stand Mean Difference (SMD) of 7.38 (95% CI: 5.51-9.26).
  • GLP-1RA improved 6-minute walk distance by 17.69% (95% CI: 11.87-23.34) compared to placebo.

Sources:

  • Glp-1ra Versus Placebo In Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: an Updated Meta-analysis of Randomized Controlled Trials. International Journal of Cardiology, 2025;438.
  • University of Illinois, Carle Foundation Hospital, Dept. of Cardiology, Urbana, IL, United States.
  • International Journal of Cardiology can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland.

Read more